Instantaneous wave-free ratio guided multivessel revascularisation during percutaneous coronary intervention for acute myocardial infarction: study protocol of the randomised controlled iMODERN trial by Beijnink, C.W.H. et al.






The following full text is a publisher's version.
 
 





Please be advised that this information was generated on 2021-11-01 and may be subject to
change.
1Beijnink CWH, et al. BMJ Open 2021;11:e044035. doi:10.1136/bmjopen-2020-044035
Open access 
Instantaneous wave- free ratio guided 
multivessel revascularisation during 
percutaneous coronary intervention for 
acute myocardial infarction: study 
protocol of the randomised controlled 
iMODERN trial
Casper W H Beijnink   ,1 Troels Thim,2 Dirk Jan van der Heijden,3 Igor Klem,4 
Rasha Al- Lamee,5 Jacqueline L Vos,1 Yvonne Koop   ,1 Marcel G W Dijkgraaf   ,6 
Marcel A M Beijk,7 Raymond J Kim,4 Justin Davies,8 Luis Raposo,9 
Sérgio B Baptista,10 Javier Escaned,11 Jan J Piek,7 Michael Maeng,2 
Niels van Royen,1 Robin Nijveldt   1
To cite: Beijnink CWH, 
Thim T, van der Heijden DJ, 
et al.  Instantaneous wave- 
free ratio guided multivessel 
revascularisation during 
percutaneous coronary 
intervention for acute 
myocardial infarction: 
study protocol of the 
randomised controlled 
iMODERN trial. BMJ Open 
2021;11:e044035. doi:10.1136/
bmjopen-2020-044035
 ► Prepublication history and 
additional material for this paper 
is available online. To view these 
files, please visit the journal 
online (http:// dx. doi. org/ 10. 
1136/ bmjopen- 2020- 044035).
Received 24 August 2020
Revised 05 December 2020
Accepted 18 December 2020
For numbered affiliations see 
end of article.
Correspondence to
Professor Robin Nijveldt;  
 robin@ nijveldt. net
Protocol
© Author(s) (or their 
employer(s)) 2021. Re- use 
permitted under CC BY- NC. No 
commercial re- use. See rights 
and permissions. Published by 
BMJ.
ABSTRACT
Introduction Recent randomised clinical trials showed 
benefit of non- culprit lesion revascularisation in ST- 
elevation myocardial infarction (STEMI) patients. However, 
it remains unclear whether revascularisation should be 
performed at the index procedure or at a later stage.
Methods and analysis The instantaneous wave- free 
ratio (iFR) Guided Multivessel Revascularisation During 
Percutaneous Coronary Intervention for Acute Myocardial 
Infarction trial is a multicentre, randomised controlled 
prospective open- label trial with blinded evaluation of 
endpoints. After successful primary percutaneous coronary 
intervention (PCI), eligible STEMI patients with residual 
non- culprit lesions are randomised, to instantaneous 
wave- free ratio guided treatment of non- culprit lesions 
during the index procedure versus deferred cardiac 
MR- guided management within 4 days to 6 weeks. The 
primary endpoint of the study is the combined occurrence 
of all- cause death, recurrent myocardial infarction and 
hospitalisation for heart failure at 12 months follow- up. 
Clinical follow- up includes questionnaires at 3 months and 
outpatient visits at 6 months and 12 months after primary 
PCI. Furthermore, a cost- effectiveness analysis will be 
performed.
Ethics and dissemination Permission to conduct this 
trial has been granted by the Medical Ethical Committee of 
the Amsterdam University Medical Centres (loc. VUmc, ID 
NL60107.029.16). The primary results of this trial will be 
shared in a main article and subgroup analyses or spin- off 
studies will be shared in secondary papers.
Trial registration number NCT03298659.
BACKGROUND
Primary percutaneous coronary intervention 
(pPCI) is the cornerstone of ST- elevation 
myocardial infarction (STEMI) treatment.1 
However, approximately 50% of STEMI 
patients have multivessel coronary artery 
disease (MVD/CAD), defined as non- culprit 
lesions with a stenosis severity >50%.2 Patients 
with MVD have an increased cardiovascular 
morbidity, with a 2.5- fold increase in mortality 
after 1 year.3 In stable CAD, it was already 
known that fractional flow reserve (FFR)- 
guided revascularisation reduces the need for 
repeat revascularisation (HR 0.13, 95% CI 0.06 
to 0.30, p<0.001) without added procedural 
risk.4 However, a routine invasive strategy does 
not affect the hard endpoints of death, recur-
rent infarction or hospital admission for heart 
failure or cardiac arrest in stable CAD.5
Strengths and limitations of this study
 ► This is the first randomised controlled trial that 
specifically addresses non- culprit lesion treatment 
timing.
 ► Ischemia- proven non- culprit lesions receive treat-
ment in both trial arms, potentially reducing non- 
necessary treatment.
 ► The open- label nature of the instantaneous wave- 
free ratio Guided Multivessel Revascularisation 
During Percutaneous Coronary Intervention for 
Acute Myocardial Infarction facilitates treatment 
bias as patients in the deferred arm knowingly have 
non- culprit lesions which may require treatment in 
the future.
 ► The trial does not have an angiography- guided 
control arm, consisting of complete revascularisa-
tion without physiological guidance, although this 
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Contrary to stable CAD, the benefit of non- culprit 
lesion revascularisation differs in the setting of STEMI, as 
the Preventive Angioplasty in Acute Myocardial Infarction 
(PRAMI) trial found that angiography- guided PCI of non- 
culprit lesions reduced the incidence of the combined 
endpoint of cardiac death, nonfatal MI, and refractory 
angina (n=465, HR 0.35, 95% CI 0.21 to 0.58).6 The 
CvLPRIT trial, similar in design but with a smaller sample 
size (n=296), showed a significant reduction of urgent 
revascularisation in the complete PCI group.7 The addi-
tion of FFR- measurements to the study protocol yielded 
similar results in the more recent DANAMI-3- PRIMULTI 
and COMPARE ACUTE trials, reducing repeat revascular-
isation in the complete PCI group.8 9 The results of these 
randomised controlled trials (RCT’s) are summarised 
in table 1 and demonstrate that non- culprit PCI, either 
during pPCI or later during index hospital admission, is 
superior to a conservative approach.
As a result, the 2017 ESC guidelines were updated 
to recommend that PCI of a non- culprit lesion should 
be considered in STEMI patients prior to hospital 
discharge.1 However, the most appropriate timing of 
non- culprit PCI remains unknown. Whether complete 
revascularisation should be achieved during the index 
procedure or as part of an outpatient approach is 
unclear and has not yet been evaluated in an RCT. This 
leads to divergent clinical practices with complete revas-
cularisation either as index—or a staged procedure. 
The primary aim of the ongoing instantaneous wave- 
free ratio (iFR) Guided Multi- vessel Revascularisation 
During Percutaneous Coronary Intervention for Acute 
Myocardial Infarction (iMODERN) trial is to determine 
the optimal timing for non- culprit lesion treatment 
after STEMI, by comparing non- culprit PCI during the 
index procedure to protocolised staged PCI, guided by 
cardiac MR (CMR), within 4 days to 6 weeks after the 
index procedure.
Table 1 Studies of non- culprit lesion revascularisation versus conservative management
Study reference n Design
Primary outcome and 
follow- up Main study findings
Wald et al, PRAMI, 
NEJM 20136
465 Angiographic non- culprit 




non- fatal MI or refractory 
angina at 23 months.
Non- culprit PCI reduces incidence 
of non- fatal MI (HR 0.32, 95% CI 
0.13 to 0.75) and refractory angina 
(HR 0.35, 95% CI 0.18 to 0.69) but 
not mortality (HR 0.34, 95% CI 0.11 
to 1.08).
Gershlick et al, 
CVLPRIT, JACC 20157
296 Immediate angiographic 
non- culprit PCI or in- 
hospital non- culprit PCI 
vs conservative treatment.
Combined outcome of 
all- cause death, non- fatal 
MI, ischaemia- driven 
revascularisation or heart 
failure within 12 months.
Non- culprit treatment reduces 
MACE (n=15 vs n=31, p=0.009) 
but none of the individual MACE 
components are significantly lower.
Engstrom et al, 
DANAMI-3- PRIMULTI, 
Lancet 20158
627 FFR- guided in- hospital 
PCI of non- culprit lesions 
versus conservative 
treatment.
All- cause death, 
nonfatal MI or repeated 
revascularisation at 
12 months.
FFR- guided non- culprit PCI 
significantly reduces MACE (13% vs 
22%, p=0.004), caused exclusively 
by ischemia- driven revascularisation 
on an individual level (5% vs 17%, 
p<0.0001).
Smits et al, COMPARE 
ACUTE, NEJM 20179
885 1:2 randomisation to 
direct FFR- guided 
PCI (n=295) or FFR 
measurement without PCI 
(n=590).
All- cause death non- 
fatal MI, repeated 
revascularisation or 
cerebrovascular events at 
12 months.
FFR- guided PCI reduces the 
combined endpoint, mainly driven 
by less revascularisation, both 
urgent and elective (6.1% vs 17.5%, 
p<0.001).
Mehta et al, 
COMPLETE, NEJM 
201913
4.041 Angiography or 
physiology- guided PCI, 
either in- hospital or 
<45 days at the discretion 
of the operator, versus 
conservative treatment.
Combined outcome of 
cardiovascular death or 
MI, coprimary endpoint 
included ischemia- driven 
revascularisation.
Complete PCI strategy resulted 
in reduction of first coprimary 
endpoint: 7.8% vs 10.5%, p=0.004). 
When ischemia- driven revasc 
was included, benefits became 
more apparent (8.9% vs 16.7%, 
p<0.001). No difference was found 
between complete treatment during 
index admission versus a deferred 
strategy (p=0.62).
eGFR, estimated Glomerular Filtration Rate; FFR, fractional flow reserve; MACE, major adverse cardiac events; MI, myocardial infarction; 
pPCI, primary percutaneous coronary intervention; PRAMI, Preventive Angioplasty in Acute Myocardial Infarction.
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Methods iMODERN trial design and population
The trial will be described in this paper according to the 
2013 Standard Protocol Items: Recommendations for 
Interventional Trials statement.10 Participating centres 
are situated throughout Europe. A total of 1146 STEMI 
patients will be randomised in a 1:1 ratio to iFR- guided 
non- culprit lesion PCI during the index procedure or to 
staged stress perfusion CMR- guided non- culprit lesion 
PCI, performed within 4 days to 6 weeks. The hypothesis 
of the study is that the abolishment of myocardial isch-
emia by also directly treating physiologically significant 
non- culprit coronary stenoses will lead to a reduction in 
the composite primary end point of all- cause death, recur-
rent MI, or hospitalisation for heart failure at 12 months 
follow- up, with a resultant reduction of healthcare costs, 
as compared with a delayed complete revascularisation 
strategy.
Trial eligibility criteria
STEMI patients with one or more non- culprit lesions 
amenable for PCI are included immediately following 
successful treatment of the culprit lesion. All eligible 
patients will be treated in accordance with the 2017 ESC 
guidelines.1 Patients with at least one 50%–90% (by visual 
estimation) non- culprit coronary artery lesion that is suit-
able for revascularisation with PCI, who have no exclu-
sion criteria, will be asked for verbal consent immediately 
after the pPCI by the treating physician (please refer to 
boxes 1 and 2 for an overview of all inclusion and exclu-
sion criteria).
Randomisation and treatment
Patients will be randomised using the central Syncrony 
EDC online random number generator, using a permuted 
block design per centre. Randomisation will be stratified 
for non- culprit lesions in the proximal or mid left ante-
rior descending artery (LAD). A flow chart of the study 
treatments is provided in figure 1. If stress perfusion CMR 
is unfeasible for clinical or practical reasons, the physi-
cian may decide for staged iFR guided revascularisation 
of the non- culprit lesions.
Index procedure non-culprit lesion assessment
In patients randomised to undergo iFR- guided non- 
culprit lesion treatment during the index procedure, a 
pressure wire (Philips Volcano, Rancho Cordova, USA) 
assessment will be performed. Briefly, the pressure will be 
normalised to the aortic pressure and then the wire will 
be advanced past the non- culprit lesion as distal as prac-
tically possible. Then, a pressure tracing will be obtained 
during at least 10 cardiac cycles, after which the iFR can 
be calculated as the ratio between the distal pressure and 
the proximal pressure in the wave- free period.11 After the 
measurement, a drift check will be performed. If the drift 
value exceeds±0.02, both normalisation and iFR measure-
ment will be repeated. By protocol, non- culprit lesions 
with an iFR value ≤0.89 will be revascularised with PCI 
during the index procedure or within a bailout window of 
24 hours. Figure 2 represents a case example of a patient 
with iFR- positive lesions, who underwent successful PCI.
Staged CMR-guided non-culprit lesion assessment
CMR will be performed between 4 days and 6 weeks 
after the index procedure. Clinical 1.5 or 3T scanners 
with a phased array cardiac receiver coil will be used. 
All images will be ECG- gated and acquired during mild 
end- expiration breath holding, using a dedicated CMR 
protocol. First, the long axis cine images will be acquired 
with a standard balanced steady- state free precession 
sequence. This will be followed by a test run at the basal, 
mid and apical short axis of the heart for the stress perfu-
sion protocol. On correct axis planning, adenosine will 
be administered at 140 μg/kg/min intravenously for 
4 min, or 210 μg/kg/min if no haemodynamic response is 
observed. After 4 min, a gadolinium- based contrast agent 
will be injected at 4.5 mL/s. After arrival of the contrast 
agent in the right ventricle, breath- hold will be performed, 
to acquire the saturation- recovery single- shot gradient- 
echo sequence images. Normally, the contrast agent 
washes into the myocardium at a similar rate throughout 
the entire myocardium. However, contrast wash- in to the 
myocardium will be impaired in the presence of one or 
more coronary stenoses, observed as a hypoenhanced 
region amid regions that display clear contrast wash- in 
on a stress sequence and visually reported as a perfusion 
defect. Subsequently, myocardial function will be assessed 
completely through continuous short axis slides, covering 
the entire left ventricle. This will be followed by late gado-
linium enhancement (LGE) imaging of all long axis and 
Box 1 Inclusion criteria
 ► Age 18 years years and older.
 ► Clinical presentation of ST- elevation myocardial infarction and suc-
cessful primary percutaneous coronary intervention (PCI) within 12 
hours from onset of symptoms.
 ► One or more other, non- culprit coronary artery lesions of >50% ste-
nosis and feasible to be revascularised with PCI (ie, minimal diam-
eter 2 mm).
Box 2 Exclusion criteria
 ► History of ST- elevation myocardial infarction or coronary artery by-
pass graft.
 ► Haemodynamic instability, respiratory failure, Killip class ≥III.
 ► Known estimated Glomerular Filtration rate (eGFR) <30 mL/min.
 ► Known contraindications for stress cardiac MR (eg, severe claustro-
phobia, metal implants, severe renal failure, severe asthma).
 ► Refusal or inability to provide informed consent.
 ► Life expectancy due to non- cardiovascular co- morbidity of less than 
12 months months.
 ► Chronic total occlusion.
 ► Left main stem stenosis (>50%).
 ► Residual non- culprit lesion in infarct coronary artery.
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short axis slices at 10 min postcontrast administration with 
a 2 dimensional inversion recovery, spoiled gradient echo 
sequence and custom optimal inversion time to correctly 
null normal myocardium. Finally, rest perfusion images 
will be acquired.
Central image collection
All angiography and CMR images will be collected 
centrally on a web- based platform (Webpax, Heart 
Imaging Technologies, Durham, USA) The iFR assess-
ments will be made locally. A second read for quality 
assessment will be done by Cerebria (Cerebria, St. Albans, 
UK). A CMR form, containing the location of culprit and 
non- culprit lesions, scan details and contrast dosage, 
will be sent to the core lab. The core lab physician will 
use information from the CMR form and evaluate the 
coronary angiogram to assign the non- culprit lesion to a 
myocardial territory subtended by the poststenotic coro-
nary artery. Then, visual interpretation of stress and rest 
perfusion CMR images will be performed to determine if 
there is ischaemia in the non- culprit lesion. Non- culprit 
lesions will be deemed positive if there is a perfusion 
defect in at least one myocardial segment, or more than 
6% of the myocardium, in the territory of the designated 
non- culprit lesion. CMR core lab reports are used to 
guide revascularisation decisions and will be returned 
to the investigational site within 24 hours. If positive for 
ischaemia, patients will undergo subsequent PCI of non- 
culprit lesions.
Follow-up
Patients will visit the outpatient clinic at 6 months and 
12 months follow- up for a clinical evaluation. This evalu-
ation will include a brief medical history, physical exam-
ination and an ECG. Cost- effectiveness and treatment 
effect will be assessed through the Medical Consumption 
Questionnaire (iMCQ), the Productivity Cost Question-
naire (iPCQ), the Seattle Angina Pectoris Questionnaire 
(SAQ), EuroQoL 5- Dimension 5- Level questionnaire 
(EQ- 5D- 5L), and the Minnesota Living with Heart Failure 
Figure 1 The study flow chart. An overview of the randomisation process, the study procedures, and patient follow- up. CMR, 
cardiac MR; iFR, instantaneous wave- free ratio; LAD, left anterior descending; PCI, percutaneous coronary intervention; STEMI, 
ST- elevation myocardial infarction.
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Questionnaire (MLHQ). At 1 hour, 7 weeks and 3 months 
follow- up the EQ- 5D- 5L, SAQ, iMCQ and iPCQ question-
naires will be completed. At 12 months follow- up, the 
EQ- 5D- 5L, MLHQ, SAQ, iMCQ and iPCQ will be taken, 
to add an incremental perspective on cost and benefit. 
Follow- up will be completed with a telephone follow- up 
after 3 and 5 years. The occurrence of all- cause death, 
recurrent MI, all- cause hospital admission, stroke, de 
novo heart failure, unstable angina, stent thrombosis 
(defined and categorised using the criteria proposed by 
the Academic Research Consortium,12 repeat coronary 
angiography and any new unplanned revascularisation 
will be documented during each follow- up visit in the 
anonymised Syncrony EDC module. Target lesion failure 
will be scored, defined as treatment failure of one of the 
non- culprit lesions, including cardiac death, MI or clin-
ically driven target lesion revascularisation by percuta-
neous or coronary artery bypass surgery. No additional 
blood sampling or imaging will be performed as part of 
the study follow- up.
Patient involvement
All enrolled patients will receive the main outcomes of 
this trial by mail in their native language. The results 
will also be shared on the trial website. Furthermore, the 
Dutch Heart Council will aid in the dissemination of trial 
results towards Dutch patient support groups.
Endpoints and statistical analysis
The combined primary endpoint is a composite of all- 
cause death, recurrent MI, and hospitalisation for heart 
failure at 12 months follow- up.
Secondary endpoints include the primary end point 
at 6 months, cardiac death, ischaemic and haemor-
rhagic stroke, transient ischaemic attack, major bleeding, 
unstable angina, revascularisation, coronary angiog-
raphy, stent thrombosis and costs related to complete, 
iFR- guided revascularisation versus CMR- guided treat-
ment (cost effectiveness analysis). Target lesion failure 
will be documented, including cardiac death, MI or 
clinically driven target lesion revascularisation by percu-
taneous or bypass surgery at 12 months, 3 years and 
5 years follow- up. All outcomes will be analysed using an 
intention- to- treat analysis, meaning that each patient will 
be analysed according to the initial randomisation group, 
regardless of the administered treatment. Finally, a cost- 
effectiveness and cost–utility analysis end point will be 
evaluated from a societal perspective with the costs per 
prevented cardiac events (all- cause mortality, recurrent 
MI and hospitalisation for heart failure) and the costs per 
quality- adjusted life year as the respective primary health 
economic outcomes. The prespecified subgroup analyses 
include diabetes mellitus vs no diabetes mellitus, female 
versus male gender, infarct lesion length terciles, infarct 
vessel terciles, time between onset of STEMI and PPCI, 
non- culprit lesion location LAD segment 6 or 7, anterior 
STEMI and troponin level above median versus below 
median.
Sample size calculation
The study is powered to assess and compare the differ-
ence in the primary end point between the iFR- guided 
revascularisation during index procedure group vs the 
CMR- guided approach after 12 months. Assuming a 
16% incidence of the primary end point in the CMR- 
guided group based on previous literature,6 153 primary 
endpoint events are needed and should be provided by 
1146 patients in order to provide the study with 80% 
power to detect a relative risk reduction of 35%, implying 
an HR of 0.63, at a two- sided alpha level of 5%.
Ethics and dissemination
Permission to conduct this trial was obtained from the 
Medical Ethical Committee of the Amsterdam University 
Figure 2 Direct lesion assessment. Angiographic 
images from a patient in the iFR- guided index procedure 
revascularisation arm. (A) Shows the culprit vessel, the RCA, 
that was treated by pPCI with 2x DES implantation at the 
black arrows. (D) Shows two non- culprit lesions for which the 
iFR value was measured (B and E). Both lesions were positive 
for ischemia (iFR D1=0.50, iFR LAD=0.84), and treated 
with additional PCI during the index procedure, after which 
total restoration of flow is seen on (C, F). D1, first diagonal 
branch; DES, drug- eluting stent; iFR, instantaneous wave- 
free ratio; LAD, left anterior descending artery; pPCI, primary 
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Medical Centres (loc. VUmc, ID NL60107.029.16). To 
solve the difficulty of acquiring informed consent during 
an emergency procedure, the research team will provide 
additional information after the index procedure and 
during initial hospital admission. Then, written consent 
will be obtained in agreement with the Declaration of 
Helsinki.
Interim source data verification and monitoring will be 
performed by ongoing central monitoring of the data, 
remote monitoring visits and onsite monitoring visits. A 
medical monitor will review all adverse events to assess 
safety trends and risks. A clinical events committee (CEC) 
will be consulted in the adjudication of adverse events of 
interest. The CEC will assess the primary and secondary 
endpoints of the trial and determines whether adverse 
events meet protocol- specific criteria of these endpoints. 
A data and safety monitoring board (DSMB) will act in an 
advisory capacity to monitor patient safety and evaluate 
the progress of the trial. The DSMB will convene three 
times during the trial, that is, when 25%, 50% and 75% 
of patients reach the 12- month follow- up milestone. To 
conclude, primary results of this trial will be published in 
a main article. Spin- off studies and subgroup analyses will 
be shared in secondary papers.
Current status
Currently, there are 33 participating centres that have 
included 524 patients (visible in online supplemental 
appendix A). The names of the participating sites and 
their PI’s are provided in online supplemental appendix 
A. Recruitment started in December 2017 and was 
expected to continue until 2021. Due to the currently 
ongoing COVID-19 outbreak, inclusion has been halted 
and follow- up visits are being done by telephone. 
Endpoint data will be collected as planned. Inclusion 
will be continued as soon as the local national public 
health institutes allow it and after the local medical 
ethics committee has been notified. As this is an interna-
tional study, it is likely that inclusion will be reinitiated at 
different timepoints at all sites based on different local 
policies.
DISCUSSION
The current trial is designed to determine, with adequate 
statistical power to detect hard clinical endpoints, the 
optimal timing for non- culprit lesion PCI in patients 
presenting with STEMI.
The results of the recently published COMPLETE 
trial support that complete revascularisation in patients 
with STEMI and multivessel disease reduces cardiovas-
cular death and MI.13 STEMI patients who are treated 
with complete revascularisation live longer and have a 
lower risk of a new MI. In its treatment arm, there was no 
difference between outcome among patients with in- hos-
pital (n=1353) or later stage PCI of non- culprit lesions 
(n=663). However, the COMPLETE trial does not answer 
the question whether an immediate or a delayed strategy 
should be chosen for non- culprit PCI, as complete revas-
cularisation was not performed during the index proce-
dure, a major difference with the current trial in which 
we speculate that immediate abolishment of non- culprit 
lesions improves hard outcomes. Therefore, in the after-
math of the COMPLETE trial, further specification of the 
right timing for non- culprit PCI in patients with STEMI 
constitutes an urgent research objective.
Direct non-culprit lesion treatment
There are several potential mechanisms by which the 
presence of stenoses in non- culprit coronary arteries may 
be associated with poorer outcomes in STEMI patients. 
At a difference with most stable patients with multivessel 
disease, complete revascularisation in acute STEMI with 
multivessel disease may have an immediate impact on 
cardiac function. This is because in STEMI patients there 
is a higher demand for flow adjacent to the infarcted 
myocardium to compensate for suddenly dysfunctional 
myocardium. Blunting of this important compensatory 
mechanism by physiologically significant stenoses in non- 
culprit vessels may lead to catastrophic consequences like 
pump failure, or to a more marked expression of the flow- 
limiting effect of the pre- existing stenoses in non- culprit 
vessels (ie, become ischaemia- generating under higher 
myocardial oxygen demand circumstances). A second 
mechanism leading to cardiovascular events in non- culprit 
territories is related to the fact that the pathobiological 
processes leading to plaque ulceration and thrombosis 
in the culprit vessel, which may be related to systemic 
inflammation, may be ongoing in non- culprit coronary 
vessels.14 15 Using optical coherence tomography, Kubo et 
al16 documented the presence of a pan- arteritis process 
of vulnerable coronary artery lesions after an MI. Thin 
fibrous caps, which are prone to plaque rupture, were 
present more frequently in the non- culprit lesions of 
acute MI patients as compared with patients with chronic 
CAD. Finally, non- culprit lesions may become particu-
larly susceptible to plaque rupture by the prothrombotic 
milieu that occurs during an MI.17
The existence of the mechanisms described above, by 
which stenoses in non- culprit vessels may amplify the 
consequences of MI in the culprit- vessel territory, provide 
a rationale for immediate treatment of ischaemic lesions 
in STEMI patients, that is, during the index procedure. 
Indeed, a recent retrospective study suggests that imme-
diate complete reperfusion reduces major adverse cardiac 
events (MACE) compared with staged reperfusion.18 
Furthermore, in light of the FAME I trial,19 it is conceiv-
able that revascularisation based on physiologic indices, 
that is, invasive pressure measurements or non- invasive 
ischemia detection, can improve outcomes as compared 
with revascularisation based solely on angiographic 
stenosis severity by reducing the need for non- necessary 
PCI, improving patient safety. In the current trial, iFR 
was chosen because it is a simpler and more cost- effective 
alternative to FFR with similar MACE in large prospec-
tive RCTs.20 21 Moreover, the iFR is relatively stable in the 
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acute setting of STEMI as it is less influenced by micro-
circulatory disturbances, an important confounder.22 23 
Additionally, iFR values as measured during index STEMI 
PCI procedures have a negative predictive value of 89% 
when compared with the iFR at a median follow- up of 
16 days (IQR 5–32 days). The iFR rises significantly during 
this period, suggesting that it is a suitable measurement 
for ruling out the presence of significant non- culprit 
CAD.24 Finally, the use of iFR, as compared with FFR, 
reduces procedure times and improves experienced 
patient comfort, as the iFR does not require adenosine 
infusion.20
Cardiac CMR-guided non-culprit lesion assessment
CMR is becoming a widely available tool that is frequently 
used for the assessment of patients with suspected CAD 
after acute MI. It is advised to perform non- invasive 
ischemia detection as a gatekeeper for coronary angi-
ography, as a stepwise protocol reduces healthcare costs 
per quality- associated lifeyear.25 CMR is a radiation- free 
non- invasive imaging method, allowing to combine the 
assessment of myocardial function, perfusion, and infarct 
size. In order to differentiate true ischemia from infarc-
tion, CMR offers the unique capability of setting apart a 
perfusion defect from irreversibly damaged myocardium 
by means of LGE with a high spatial resolution in one 
exam, as shown in figure 3. A complete CMR protocol 
provides this information within 30 min. Regarding safety, 
a stress perfusion CMR- guided approach is non- inferior 
for the prevention of MACE as compared with an FFR- 
guided approach in patients with chest pain and cardio-
vascular risk factors or a positive treadmill test, all without 
objectified CAD. This is partly because CMR- guided 
revascularisation significantly reduces the amount of PCI 
performed.26
Technical advantages and drawbacks aside, it is known 
that STEMI patients with one or more perfusion defects 
(on SPECT) show strongly improved MACE outcomes, as 
well as significantly improved survival rates, when addi-
tional PCI is performed compared with optimal medical 
therapy alone.27 This finding is in contrast with the results 
of the recent ISCHAEMIA trial in which revascularisation 
of ischaemic lesions did not improve hard endpoints in 
patients with chronic CAD, a disease that is more stable 
by nature.5 There is currently no randomised trial that 
has assessed the use of stress perfusion CMR specifically 
in the follow- up of STEMI. However, in the detection of 
ischemia in patients with suspected CAD, stress perfusion 
CMR outperforms SPECT in terms of sensitivity and spec-
ificity,28 especially in the setting of multivessel disease.29 
Furthermore, CMR is superior to SPECT for infarct delin-
eation, a finding that holds true especially for subendo-
cardial MI, which SPECT detects in 28% of cases, whereas 
CMR does so in 92%.30 Finally in comparison to PET, 
CMR is a more widely available and less costly imaging 
modality with superior spatial resolution that does not 
subject patients to potentially harmful radiation. Given 
the numerous advantages of CMR over SPECT and PET, 
CMR is the method of choice in this trial for deferred 
non- culprit ischaemia detection.
Trial limitations
The iMODERN will not involve an angiography- guided 
treatment arm, which has been shown to be effective in 
reducing cardiovascular death and myocardial infarc-
tion.13 Second, the preconceived endpoint incidence 
as based on the results of the PRAMI trial seems too 
high when compared with newer, larger trials, reducing 
the trial’s ability to detect hard outcomes. To ensure 
adequate power, secondary endpoint collection will also 
be performed at 3 and 5 years. Third, the open- label 
nature of the trial will mean that patients knowingly have 
residual CAD until the deferred revascularisation proce-
dure. Any complaints of chest pain may then be linked to 
the residual disease, possibly resulting in earlier revascu-
larisation than planned per study protocol.
Implications
If direct iFR- guided complete revascularisation leads to 
improved patient outcomes and more cost- effectiveness as 
compared with CMR- guided complete revascularisation, 
complete treatment of all obstructive coronary stenoses 
during the index procedure will be recommended in 
STEMI patients, reducing the need for additional proce-
dures with concomitant reduction in healthcare costs.
Figure 3 Typical example of a patient from the CMR- 
guided complete revascularisation arm. (A) The dotted arrow 
indicates thrombus and occlusion of the RCA. (B) A non- 
culprit lesion of 70%–80% in the prox and mid LAD (solid 
line); (C, D) stress perfusion CMR was performed 4 weeks 
after primary PCI, demonstrating two perfusion defects, of 
which the solid line indicates ischemia from the non- culprit 
LAD lesion (C), without any late gadolinium enhancement 
and a perfusion defect in the RCA territory caused by the 
subendocardial infarct (D, dotted line). CMR, cardiac MR; 
LV, left ventricle; LAD, left anterior descending artery; PCI, 
percutaneous coronary intervention; P, papillary muscle; RCA, 
right coronary artery; RV, right ventricle.
by copyright.
 on A













pen: first published as 10.1136/bm




8 Beijnink CWH, et al. BMJ Open 2021;11:e044035. doi:10.1136/bmjopen-2020-044035
Open access 
Author affiliations
1Cardiology, Radboudumc, Nijmegen, The Netherlands
2Department of Cardiology, Aarhus University Hospital, Aarhus N, Denmark
3Cardiology, Medisch Centrum Haaglanden, Den Haag, The Netherlands
4Cardiology, Duke University Medical Center, Durham, North Carolina, USA
5Cardiology, Imperial College London Faculty of Medicine, London, UK
6Clinical Epidemiology, Biostatistics and Bioinformatics, Amsterdam UMC - Locatie 
AMC, Amsterdam, The Netherlands
7Cardiology, Amsterdam UMC Locatie AMC, Amsterdam, The Netherlands
8Faculty of Medicine, Imperial College London, London, UK
9Cardiology, Centro Hospitalar de Lisboa Ocidental EPE, Lisboa, Portugal
10Cardiology Department, Hospital Fernando Fonseca, Amadora, Portugal
11Interventional Cardiology, Hospital Clínico Universitario San Carlos, Madrid, Spain
Twitter Yvonne Koop @YvonneKoop_
Contributors The primary author CWHB was responsible for the drafting of the 
manuscript and the collection and interpretation of relevant sources. RN (senior 
author) and NvR conceived the trial protocol, acquired the necessary funding for the 
trial, and were coresponsible for drafting the manuscript and interpreting the used 
literature. The coauthors TT, DvdH, MB and RA- L are senior members of the study 
team, who read the article and provided substantial intellectual input. JD, LR, SB, 
JE, MM and JJP are members of the steering committee, who read the article and 
provided important revisions to the discussion. RA- L was responsible for textual 
corrections. JLV, IK and RK read the article and helped to improve the Methods 
section. YK provided statistical advice. MGWD revised the economical analysis. All 
authors have read the final version of the article and agree with its content.
Funding Philips and Biotronik supported this investigator- initiated study by an 
unrestricted grant to the Radboudumc (no grant number). In addition, the study is 
financed by the Ministry of Economic Affairs of the Netherlands by a PPP allowance 
(grant number LSHM 16036).
Competing interests None declared.
Patient consent for publication Not required.
Provenance and peer review Not commissioned; externally peer reviewed.
Supplemental material This content has been supplied by the author(s). It has 
not been vetted by BMJ Publishing Group Limited (BMJ) and may not have been 
peer- reviewed. Any opinions or recommendations discussed are solely those 
of the author(s) and are not endorsed by BMJ. BMJ disclaims all liability and 
responsibility arising from any reliance placed on the content. Where the content 
includes any translated material, BMJ does not warrant the accuracy and reliability 
of the translations (including but not limited to local regulations, clinical guidelines, 
terminology, drug names and drug dosages), and is not responsible for any error 
and/or omissions arising from translation and adaptation or otherwise.
Open access This is an open access article distributed in accordance with the 
Creative Commons Attribution Non Commercial (CC BY- NC 4.0) license, which 
permits others to distribute, remix, adapt, build upon this work non- commercially, 
and license their derivative works on different terms, provided the original work is 
properly cited, appropriate credit is given, any changes made indicated, and the use 
is non- commercial. See: http:// creativecommons. org/ licenses/ by- nc/ 4. 0/.
ORCID iDs
Casper W H Beijnink http:// orcid. org/ 0000- 0003- 1777- 9586
Yvonne Koop http:// orcid. org/ 0000- 0001- 6150- 0859
Marcel G W Dijkgraaf http:// orcid. org/ 0000- 0003- 0750- 8790
Robin Nijveldt http:// orcid. org/ 0000- 0003- 1530- 6363
REFERENCES
 1 Ibanez B, James S, Agewall S, et al. 2017 ESC guidelines for the 
management of acute myocardial infarction in patients presenting 
with ST- segment elevation: the task force for the management of 
acute myocardial infarction in patients presenting with ST- segment 
elevation of the European Society of cardiology (ESC). Eur Heart J 
2018;39:119–77.
 2 Park D- W, Clare RM, Schulte PJ, et al. Extent, location, and 
clinical significance of non- infarct- related coronary artery disease 
among patients with ST- elevation myocardial infarction. JAMA 
2014;312:2019–27.
 3 Sorajja P, Gersh BJ, Cox DA, et al. Impact of multivessel disease on 
reperfusion success and clinical outcomes in patients undergoing 
primary percutaneous coronary intervention for acute myocardial 
infarction. Eur Heart J 2007;28:1709–16.
 4 De Bruyne B, Pijls NHJ, Kalesan B, et al. Fractional flow reserve- 
guided PCI versus medical therapy in stable coronary disease. N 
Engl J Med 2012;367:991–1001.
 5 Maron DJ, Hochman JS, Reynolds HR, et al. Initial invasive or 
conservative strategy for stable coronary disease. N Engl J Med 
2020;382:1395–407.
 6 Wald DS, Morris JK, Wald NJ, et al. Randomized trial of 
preventive angioplasty in myocardial infarction. N Engl J Med 
2013;369:1115–23.
 7 Gershlick AH, Khan JN, Kelly DJ, et al. Randomized trial of 
complete versus lesion- only revascularization in patients 
undergoing primary percutaneous coronary intervention for STEMI 
and multivessel disease: the CvLPRIT trial. J Am Coll Cardiol 
2015;65:963–72.
 8 Engstrøm T, Kelbæk H, Helqvist S, et al. Complete revascularisation 
versus treatment of the culprit lesion only in patients with ST- 
segment elevation myocardial infarction and multivessel disease 
(DANAMI-3—PRIMULTI): an open- label, randomised controlled trial. 
The Lancet 2015;386:665–71.
 9 Smits PC, Abdel- Wahab M, Neumann F- J, et al. Fractional flow 
reserve- guided multivessel angioplasty in myocardial infarction. N 
Engl J Med 2017;376:1234–44.
 10 Chan A- W, Tetzlaff JM, Altman DG, et al. SPIRIT 2013 statement: 
defining standard protocol items for clinical trials. Ann Intern Med 
2013;158:200–7.
 11 Sen S, Escaned J, Malik IS, et al. Development and validation 
of a new adenosine- independent index of stenosis severity from 
coronary wave- intensity analysis: results of the advise (adenosine 
vasodilator independent stenosis evaluation) study. J Am Coll Cardiol 
2012;59:1392–402.
 12 Garcia- Garcia HM, McFadden EP, Farb A, et al. Standardized end 
point definitions for coronary intervention trials: the academic 
research Consortium-2 consensus document. Circulation 
2018;137:2635–50.
 13 Mehta SR, Wood DA, Storey RF, et al. Complete revascularization 
with multivessel PCI for myocardial infarction. N Engl J Med 
2019;381:1411–21.
 14 Joshi NV, Toor I, Shah ASV, et al. Systemic atherosclerotic 
inflammation following acute myocardial infarction: myocardial 
infarction begets myocardial infarction. J Am Heart Assoc 
2015;4:e001956.
 15 Han Y, Jing J, Tu S, et al. St elevation acute myocardial infarction 
accelerates non- culprit coronary lesion atherosclerosis. Int J 
Cardiovasc Imaging 2014;30:253–61.
 16 Kubo T, Imanishi T, Kashiwagi M, et al. Multiple coronary lesion 
instability in patients with acute myocardial infarction as determined 
by optical coherence tomography. Am J Cardiol 2010;105:318–22.
 17 Dutta P, Courties G, Wei Y, et al. Myocardial infarction accelerates 
atherosclerosis. Nature 2012;487:325–9.
 18 Tovar Forero MN, Scarparo P, den Dekker W, et al. Revascularization 
strategies in patients presenting with ST- elevation myocardial 
infarction and multivessel coronary disease. Am J Cardiol 
2020;125:1486–91.
 19 Tonino PAL, De Bruyne B, Pijls NHJ, et al. Fractional flow reserve 
versus angiography for guiding percutaneous coronary intervention. 
N Engl J Med 2009;360:213–24.
 20 Davies JE, Sen S, Dehbi H- M, et al. Use of the instantaneous 
Wave- free ratio or fractional flow reserve in PCI. N Engl J Med 
2017;376:1824–34.
 21 Götberg M, Christiansen EH, Gudmundsdottir IJ, et al. Instantaneous 
Wave- free ratio versus fractional flow reserve to guide PCI. N Engl J 
Med 2017;376:1813–23.
 22 van der Hoeven NW, Janssens GN, de Waard GA, et al. Temporal 
changes in coronary hyperemic and resting hemodynamic indices in 
Nonculprit vessels of patients with ST- segment elevation myocardial 
infarction. JAMA Cardiol 2019;4:736–44.
 23 Escaned J, Ryan N, Mejía- Rentería H, et al. Safety of the deferral of 
coronary revascularization on the basis of instantaneous Wave- Free 
ratio and fractional flow reserve measurements in stable coronary 
artery disease and acute coronary syndromes. JACC Cardiovasc 
Interv 2018;11:1437–49.
 24 Thim T, Götberg M, Fröbert O, et al. Nonculprit Stenosis Evaluation 
Using Instantaneous Wave- Free Ratio in Patients With ST- 
Segment Elevation Myocardial Infarction. JACC Cardiovasc Interv 
2017;10:2528–35.
 25 Ge Y, Pandya A, Steel K, et al. Cost- Effectiveness analysis of stress 
cardiovascular magnetic resonance imaging for stable chest pain 
syndromes. JACC Cardiovasc Imaging 2020;13:1505–17.
by copyright.
 on A













pen: first published as 10.1136/bm




9Beijnink CWH, et al. BMJ Open 2021;11:e044035. doi:10.1136/bmjopen-2020-044035
Open access
 26 Nagel E, Greenwood JP, McCann GP, et al. Magnetic resonance 
perfusion or fractional flow reserve in coronary disease. N Engl J 
Med 2019;380:2418–28.
 27 Erne P, Schoenenberger AW, Burckhardt D, et al. Effects of 
percutaneous coronary interventions in silent ischemia after 
myocardial infarction: the SWISSI II randomized controlled trial. 
JAMA 2007;297:1985–91.
 28 Schwitter J, Wacker CM, van Rossum AC, et al. MR- IMPACT: 
comparison of perfusion- cardiac magnetic resonance with single- 
photon emission computed tomography for the detection of coronary 
artery disease in a multicentre, multivendor, randomized trial. Eur 
Heart J 2008;29:480–9.
 29 Greenwood JP, Maredia N, Younger JF, et al. Cardiovascular 
magnetic resonance and single- photon emission computed 
tomography for diagnosis of coronary heart disease (CE- MARC): a 
prospective trial. Lancet 2012;379:453–60.
 30 Wagner A, Mahrholdt H, Holly TA, et al. Contrast- Enhanced MRI 
and routine single photon emission computed tomography (SPECT) 
perfusion imaging for detection of subendocardial myocardial 
infarcts: an imaging study. Lancet 2003;361:374–9.
by copyright.
 on A













pen: first published as 10.1136/bm






Appendix A – Participating centres per country 
The Netherlands: 
Radboud University Medical Centre, Nijmegen - R. Nijveldt, MD PhD, N. van Royen, MD PhD; 
Amsterdam University Medical Centre, Amsterdam - J.J. Piek, MD PhD, R.N. Planken, MD PhD; 
Tergooi Hospital, Blaricum - S.L. Brinckman, MD, C.E. Saraber, MD; Maastricht University Medical 
Centre, Maastricht - S.C.A.M. Bekkers, MD PhD, A.W.J. van ‘t Hof, MD PhD; Zuyderland Medical 
Centre, Heerlen - M. Ilhan, MD, T. Lenderink, MD PhD; Onze Lieve Vrouwe Gasthuis, Amsterdam - R.J. 
van der Schaaf, MD PhD, L. van Heerebeek, MD PhD; Amphia Medical Centre, Breda - M. Meuwissen, 
MD PhD, M.M. Krouwels, MD; Rijnstate Medical Centre, Arnhem - L.H. Piers, MD PhD; University 
Medical Centre Groningen, Groningen - E. Lipsic, MD PhD, G. Pundziute-do Prado, MD PhD; 
Haaglanden Medical Centre, The Hague - D.J. van der Heijden, MD PhD, P.R.M. van Dijkman, MD PhD; 
Treant Scheper Medical Centre, Emmen - L. Kleijn, MD PhD, R. Anthonio, MD; Canisius Wilhelmina 
Hospital, Nijmegen, the Netherlands - M.E.R. Gomes, MD PhD. 
Denmark: 
Aarhus University Hospital, Skejby - T. Thim, MD PhD, C. Alcaraz Frederiksen, MD PhD;  
United Kingdom: 
Hammersmith Hospital, London - S. Sen, MD PhD, G. Cole, MD PhD; Royal United Hospital Bath, Bath 
- D. Augustine, MD PhD, D. McKenzie, MD PhD; Basildon and Thurrock University Hospitals, Basildon - 
K. Tang, MD, S. Gedela, MD PhD; St Bartholomew’s Hospital, London - D. Jones, MD PhD, S. Petersen, 
MD PhD; Manchester University Hospital, Manchester - M. Motwani, MD PhD, M. El-Omar, MD PhD; 
Freeman Hospital, Newcastle - V. Kunadian, MD PhD, A. Bandali, MD PhD;  
Luxembourg: 
Centre Hospitalier de Luxembourg, Luxembourg - A. Codreanu, MD PhD, P. Degrell, MD PhD;  
Switzerland:  
University Hospital Geneva, Geneva - J.F. Iglesias, MD PhD, D. Carballo, MD PhD; Kantonsspital 
Aarau, Aarau - M. Giacchi, MD PhD, P. Anabitarte, MD PhD; Kantonsspital St. Gallen, St. Gallen - D. 
Weilenmann, MD PhD, L. Joerg, MD PhD;  
Belgium: 
University Hospital Gent, Gent - P. Kayaert, MD PhD, D. Devos, MD PhD; 
Portugal: 
Centro Hospitalar de Lisboa Occidental, Lisbon - L. Raposo, MD PhD, A. Ferreira, MD; Hospital Prof. 
Doutor Fernando de Fonseca, Amadora - S.B. Baptista, MD PhD; Hospital Santa Maria, Lisbon, P. 
Canas da Silva, MD PhD, A. Almeida, MD PhD;  
Spain: 
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Hospital Clinico Universitario, Valencia - J. Sanchis, MD PhD, M. Pilar Lopez-Lereu, MD PhD; Hospital 
Clinico San Carlos, Madrid, Spain - J. Escaned, MD PhD, A. Bustos, MD PhD; University Hospital Vall 
d’Hebron, Barcelona - R. Palomares, MD PhD, B. Garcia del Blanco, MD PhD; 
Italy: 
IRCSS Humanitas, Rozzano - L. Monti, MD PhD, G. Stefanini, MD PhD; 
Slovenia: 
University Medical Centre Ljubljana, Ljubljana - T. Podlesnikar, MD PhD, M. Bunc, MD PhD.  
Czech Republic: 
St. Anne’s Faculty Hospital, Brno, Czech - R. Panovsky, MD PhD, O. Hlinomaz, MD PhD; 
Thailand: 
King Chulalongkorn Memorial Hospital, Bangkok, Thailand - P. Chattranukulchai, MD, S. 
Srimahachota, MD PhD; Ramathibodi Hospital, Bangkok, Thailand - T. Tangcharoen, MD PhD, P. 
Pienvichit, MD PhD; 
Australia:  
Royal North Shore and North Shore Private Hospitals, Sydney, Australia - R. Bhindi, MD PhD;  
New Zealand: 
Christchurch hospital, Christchurch New Zealand - A. Puri, MD PhD, R. Keenan, MD PhD; 
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